Zentalis Pharmaceuticals, Inc. financial data

Symbol
ZNTL on Nasdaq
Industry
Pharmaceutical Preparations
Location
10275 Science Center Drive, Suite 200, San Diego, CA
Fiscal year end
December 31
Former names
Zentalis Pharmaceuticals, LLC (to 4/6/2020), Zeno Pharma, LLC (to 9/5/2019)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 749 % -14.3%
Debt-to-equity 25.6 % +13.8%
Return On Equity -43.9 % +30%
Return On Assets -35 % +31.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.3M shares +0.71%
Common Stock, Shares, Outstanding 71.1M shares +0.72%
Entity Public Float 1.56B USD +20%
Common Stock, Value, Issued 71K USD +1.43%
Weighted Average Number of Shares Outstanding, Basic 71.1M shares +0.71%
Weighted Average Number of Shares Outstanding, Diluted 71.1M shares +0.71%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 186M USD +4.31%
General and Administrative Expense 63.5M USD +7.36%
Operating Income (Loss) -209M USD +26.1%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -238M USD -44.4%
Income Tax Expense (Benefit) 247K USD -187%
Net Income (Loss) Attributable to Parent -179M USD +37.4%
Earnings Per Share, Basic -2.42 USD/shares +47.2%
Earnings Per Share, Diluted -2.42 USD/shares +47.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41.3M USD -62.7%
Assets, Current 400M USD -24.2%
Property, Plant and Equipment, Net 5.02M USD -21.5%
Operating Lease, Right-of-Use Asset 33.4M USD -7.69%
Goodwill 3.74M USD 0%
Assets 451M USD -23.1%
Accounts Payable, Current 8.2M USD -42.5%
Employee-related Liabilities, Current 10.8M USD -2.98%
Accrued Liabilities, Current 46.7M USD +4.53%
Liabilities, Current 54.9M USD -6.86%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 40.5M USD -6.49%
Other Liabilities, Noncurrent 996K USD -39%
Liabilities 96.3M USD -7.21%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.59M USD
Retained Earnings (Accumulated Deficit) -1.01B USD -21.7%
Stockholders' Equity Attributable to Parent 354M USD -26.5%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 354M USD -26.5%
Liabilities and Equity 451M USD -23.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52M USD -5.46%
Net Cash Provided by (Used in) Financing Activities 373K USD -70.4%
Net Cash Provided by (Used in) Investing Activities 61.5M USD +46.1%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 71.1M shares +0.72%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.58M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 43.9M USD -61.2%
Deferred Tax Assets, Valuation Allowance 219M USD +36.2%
Deferred Tax Assets, Gross 230M USD +31.2%
Operating Lease, Liability 43.3M USD -5.31%
Payments to Acquire Property, Plant, and Equipment 40K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -177M USD +37.6%
Lessee, Operating Lease, Liability, to be Paid 61.9M USD -9.44%
Property, Plant and Equipment, Gross 8.97M USD -5.6%
Operating Lease, Liability, Current 2.81M USD +15.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.28M USD +7.05%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.8M USD +4.83%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18.6M USD -17.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 7.45M USD +2.38%
Deferred Tax Assets, Operating Loss Carryforwards 96.7M USD +1.35%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.21M USD -1.93%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.76M USD +4.15%
Additional Paid in Capital 1.36B USD +3.81%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.31M USD -7.23%
Deferred Tax Assets, Net of Valuation Allowance 10.4M USD -26.6%
Share-based Payment Arrangement, Expense 49.8M USD -1.52%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%